期刊文献+

Molecular dynamics simulations exploring drug resistance in HIV-1 proteases 被引量:2

Molecular dynamics simulations exploring drug resistance in HIV-1 proteases
原文传递
导出
摘要 Although HIV-1 subtype B still dominates the epidemic AIDS in developed countries,an increasing number of people in developing countries are suffering from an epidemic of non-subtype B viruses.What is worse,the efficacy of the combinational use of antiretroviral drugs is gradually compromised by the rapid development of drug resistance.To gain an insight into drug resistance, 10-ns MD simulations were simultaneously conducted on the complexes of the TL-3 inhibitor with 4 different proteases(Bwt,Bmut, Fwt and Fmut),among which the complex of the Bwt protease with the TL-3 inhibitor was treated as the control group.Detailed analyses of MD data indicated that the drug resistance of Bmut against TL-3 mainly derived from loss of an important hydrogen bond and that of Fwt was caused by the decrease of hydrophobic interactions in S1/S1'pocket,while both of the two reasons mentioned above were the cause of the Fmut protease's resistance.These results are in good agreement with the previous experiments, revealing a possible mechanism of drug resistance for the aforementioned protease subtypes against the TL-3 inhibitor.Additionally,another indication was obtained that the mutations of M36I,V82A and L90M may induce structural transforms so as to alter the inhibitor's binding mode. Although HIV-1 subtype B still dominates the epidemic AIDS in developed countries, an increasing number of people in devel- oping countries are suffering from an epidemic of non-subtype B viruses. What is worse, the efficacy of the combinational use of antiretroviral drugs is gradually compromised by the rapid development of drug resistance. To gain an insight into drug resistance, 10-ns MD simulations were simultaneously conducted on the complexes of the TL-3 inhibitor with 4 different proteases (Bwt, Bmut, Fwt and Fmut), among which the complex of the Bwt protease with the TL-3 inhibitor was treated as the control group. Detailed analyses of MD data indicated that the drug resistance of Bmut against TL-3 mainly derived from loss of an important hydrogen bond and that of Fwt was caused by the decrease of hydrophobic interactions in S 1/S 1' pocket, while both of the two reasons mentioned above were the cause of the Fmut protease's resistance. These results are in good agreement with the previous experiments, revealing a possible mechanism of drug resistance for the aforementioned protease subtypes against the TL-3 inhibitor. Additionally, another indication was obtained that the mutations of M36I, V82A and L90M may induce structural transforms so as to alter the inhibitor's binding mode.
出处 《Chinese Science Bulletin》 SCIE EI CAS 2010年第24期2677-2683,共7页
基金 supported by the National High Technology Research and Development Program of China(2006AA020406,2007AA02Z330 and2007AA02Z333) National Natural Science Foundation of China(30770502 and 30870476) Natural Science Foundation of Shanghai(10ZR1421500) as well as the State Key Laboratory of Explosion Scienceand Technology Beijing Institaute of Technology(KFJJ09-02) National Basic Research Program of China(2005CB724303)
关键词 蛋白酶抑制剂 分子动力学模拟 耐药性 HIV 艾滋病毒 MD模拟 逆转录病毒 发达国家 HIV-1 protease, drug resistance, hydrophobic interactions, hydrogen bonds, molecular dynamics simulations
  • 相关文献

参考文献28

  • 1UNAIDS. Annual Report 2009, http://data.unaids.org/pub/Report/2010/2009_annual report_en.pdf.
  • 2Caride E, Hertogs K, Larder B, et al. Genotypic and phenotypic evi- dence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Genes, 2001, 23:193-202.
  • 3Foulkes-Murzycki J E, Scott W R, Schiffer C A. Hydrophobic sliding: A possible mechanism for drug resistance in human immunodeficiency virus type 1 orotease. Structure, 2007, 15:225-233.
  • 4Abrarnowitz N, Schechter I, Berger A. On the size of the active site in protease. II. Carboxypeptidase-A. Biochem Biophys Res Commun, 1967, 29:862-867.
  • 5Schechter I, Berger A. On the size of the active site in protease. I. Papain. Biochem Biophys Res Commun, 1967, 27:157-162.
  • 6DeGruttola V, Dix L, Aquila D R, et al. The relation between base- line H1V drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a stan- dardized data analysis plan. Antivir Ther, 2000, 5:41-48.
  • 7Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV cohort study. Jama, 1999, 82:2220-2226.
  • 8Sanches M, Krauchenco S, Martins N H, et al. Swuctura/characterization of B and non-B subtypes of HIV-protease: Insights into the natural susceptibility to drug resistance development. J Mol Biol, 2007, 369:1029-1040.
  • 9Case D A, Pearlman D A, Caldwell J W, et al. AMBER 8. San Francisco: University of California, 2004.
  • 10Kollrnan P A, Cornell W D, Chipot C, et al. The development/application of "minimalist"organicfoiochemical molecular mechanic force field using a combination of ab initio calculations and experimental data. Comp Simulat Biolog Syst, 1997, 3:83-96.

同被引文献6

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部